These TKIs have transformed the treatment of NSCLC, particularly in patients with sensitizing mutations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) rearrangements, and ROS1 rearrangements [7,8]. Here, ROS1 is linked to non-small cell lung carcinoma.